Wednesday, 7 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results · Q1 FY27

Oxygenta Pharmaceutical Q1 FY27 Results: Net Loss of ₹2.1 Cr, Loss Narrows

Oxygenta Pharmaceutical Ltd reported revenue from operations of ₹37 Cr (+145.0% YoY) and a net loss of ₹2.1 Cr for Q1 FY27.

Q1 FY27 at a glance · ₹ crore
MetricQ1 FY27Q4 FY26Q1 FY26
Revenue from operations37.049.615.1
Other income0.00.20.2
Total income37.049.815.3
Profit before exceptional items & tax-2.5-1.3-8.1
Profit before tax-2.5-1.3-8.1
Net profit-2.1-1.7-6.1
Operating margin-6.8%-2.6%-52.9%

A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.

Growth
Revenue, year on year+145.00%
Operating profit, year on year+66.70%
Operating profit, quarter on quarter-10.50%
Source

BSE results filing, NSE: SSORGS. Figures extracted from the filing.

Read the filing ↗

Oxygenta Pharmaceutical Ltd: key numbers

Share price
₹48.17
Market cap
₹178.2 Cr
Revenue (annual)
₹113.0 Cr
Net profit (annual)
₹-17.57 Cr
P/E (TTM)
-13.1×Sector 47.4×
Promoter holding
56.54%+0.00% QoQ
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Oxygenta Pharmaceutical Ltd

All →
16:47 IST BSE
Annual General Meeting

Oxygenta Pharmaceutical Annual General Meeting

Oxygenta Pharmaceutical Limited conducted its 33rd Annual General Meeting on August 21, 2026, via video conferencing to discuss and adopt various corporate business resolutions.

17:06 IST BSE
Annual Report

Oxygenta Pharmaceutical Annual Report

Oxygenta Pharmaceutical has submitted its 33rd Annual Report for FY 2025-26, including the notice for the upcoming Annual General Meeting scheduled for August 21, 2026.

17:00 IST BSE
Annual General Meeting

Oxygenta Pharmaceutical Annual General Meeting

Oxygenta Pharmaceutical Limited announced its 33rd Annual General Meeting scheduled for August 21, 2026. The notice includes director appointments and adoption of the company's financial statements.

18:21 IST BSE
Other Announcement

Oxygenta Pharmaceutical Other Announcement

Oxygenta Pharmaceutical Limited has appointed M/s. PCR & Associates as its Cost Auditor for a 12-month term. This appointment follows the company's recent board meeting.

15:30 IST BSE
Board Meeting Date

Oxygenta Pharmaceutical Board Meeting Date

Oxygenta Pharmaceutical Ltd has scheduled a board meeting on July 25, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.

10:33 IST BSE
Other Announcement

Oxygenta Pharmaceutical Other Announcement

Oxygenta Pharmaceutical Ltd submitted its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with SEBI regulatory requirements.